BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36843546)

  • 21. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular changes preceding endometrial and ovarian cancer: a study of consecutive endometrial specimens from Lynch syndrome surveillance.
    Niskakoski A; Pasanen A; Lassus H; Renkonen-Sinisalo L; Kaur S; Mecklin JP; Bützow R; Peltomäki P
    Mod Pathol; 2018 Aug; 31(8):1291-1301. PubMed ID: 29588532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathologic study of endometrial dedifferentiated endometrioid adenocarcinoma: a case report.
    Shen Y; Wang Y; Shi Y; Liu J; Liu Y
    Int J Clin Exp Pathol; 2012; 5(1):77-82. PubMed ID: 22295150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SWI/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma.
    Tessier-Cloutier B; Coatham M; Carey M; Nelson GS; Hamilton S; Lum A; Soslow RA; Stewart CJ; Postovit LM; Köbel M; Lee CH
    J Pathol Clin Res; 2021 Mar; 7(2):144-153. PubMed ID: 33125840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
    Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
    Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ARID1A, BRG1, and INI1 deficiency in undifferentiated and dedifferentiated endometrial carcinoma: a clinicopathologic, immunohistochemical, and next-generation sequencing analysis of a case series from a single institution.
    Korentzelos D; Elishaev E; Zhao C; Jones MW; Soong TR; Lesnock J; Orellana T; Zeccola A; Diamantopoulos LN; Wald AI; Bhargava R
    Hum Pathol; 2022 Dec; 130():65-78. PubMed ID: 36252860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming.
    Suryo Rahmanto Y; Shen W; Shi X; Chen X; Yu Y; Yu ZC; Miyamoto T; Lee MH; Singh V; Asaka R; Shimberg G; Vitolo MI; Martin SS; Wirtz D; Drapkin R; Xuan J; Wang TL; Shih IM
    Nat Commun; 2020 Jun; 11(1):2717. PubMed ID: 32483112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma.
    Wong NKY; Llaurado Fernandez M; Kommoss FKF; Praveen Kumar P; Kim H; Liu J; Zhang G; Coatham M; Lin YY; Haegert AM; Volik S; Le Bihan S; Collins CC; Fu Y; Postovit LM; von Deimling A; Wu R; Xue H; Wang Y; Köbel M; Carey MS; Lee CH
    Gynecol Oncol; 2023 Sep; 176():162-172. PubMed ID: 37556934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
    Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
    Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
    PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A report of two cases of dedifferentiated endometrioid carcinoma: A newly described underrecognized tumor of poor prognosis.
    Boler AK; Akhtar S; Bandyopadhyay A; Roy S
    Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S91-S93. PubMed ID: 32108637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
    Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
    Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dedifferentiated carcinoma of the ovary. A case report.
    Němejcová K; Rosmusová J; Bártů M; Matěj R; Dundr P
    Cesk Patol; 2018; 54(1):33-36. PubMed ID: 29631410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dedifferentiation in Breast Metastasis of Endometrial Carcinoma: A Diagnostic Dilemma.
    Shah VI; Morgan SE; Köbel M; Lee CH; McCluggage WG
    Int J Gynecol Pathol; 2022 Jan; 41(1):35-39. PubMed ID: 33741764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?
    Silva EG; Deavers MT; Bodurka DC; Malpica A
    Int J Gynecol Pathol; 2006 Jan; 25(1):52-8. PubMed ID: 16306785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SWI/SNF-deficient malignancies of the female genital tract.
    McCluggage WG; Stewart CJR
    Semin Diagn Pathol; 2021 May; 38(3):199-211. PubMed ID: 32978032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary: Clinicopathologic Characterization With Emphasis on its Distinction From Carcinosarcoma.
    El Hallani S; Arora R; Lin DI; Måsbäc A; Mateoiu C; McCluggage WG; Nucci MR; Otis CN; Parkash V; Parra-Herran C; Longacre TA
    Am J Surg Pathol; 2021 Mar; 45(3):374-383. PubMed ID: 33565764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dedifferentiated Carcinoma of the Endometrium Associated With Low-grade Müllerian Adenosarcoma: A Clinicopathologic Case Report Including the Immunohistochemical and Molecular Profile.
    Bai S; Hutchinson LM; Meng X; Bai H; Cosar EF; Khan A; Cornejo K
    Int J Gynecol Pathol; 2020 Mar; 39(2):141-145. PubMed ID: 30908285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
    Werner HM; Berg A; Wik E; Birkeland E; Krakstad C; Kusonmano K; Petersen K; Kalland KH; Oyan AM; Akslen LA; Trovik J; Salvesen HB
    Mod Pathol; 2013 Mar; 26(3):428-34. PubMed ID: 23080032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms.
    Tafe LJ; Garg K; Chew I; Tornos C; Soslow RA
    Mod Pathol; 2010 Jun; 23(6):781-9. PubMed ID: 20305618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.